On August 30, 2024, NeuroSense Therapeutics Ltd., a clinical-stage biotech company, announced that it received a Nasdaq Minimum Bid Price Notification. The company's shares had closed below the required $1.00 minimum bid price for 30 consecutive trading days, violating Nasdaq Listing Rules. Despite the notice, NeuroSense's shares will continue to trade on the Nasdaq Capital Market under the symbol 'NRSN' during the 180-day grace period ending on February 24, 2025. The company must boost its share price to at least $1.00 for 10 consecutive business days before this deadline to regain compliance. If compliance is not achieved, NeuroSense may be granted an additional 180 days if it meets other listing standards. The company's operations remain unaffected by this notification, and it is actively monitoring its share price to address the deficiency within the compliance period. NeuroSense specializes in developing treatments for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's disease.

On August 30, 2024, NeuroSense Therapeutics Ltd., a clinical-stage biotech company, announced that it received a Nasdaq Minimum Bid Price Notification. The company's shares had closed below the required $1.00 minimum bid price for 30 consecutive trading days, violating Nasdaq Listing Rules. Despite the notice, NeuroSense's shares will continue to trade on the Nasdaq Capital Market under the symbol 'NRSN' during the 180-day grace period ending on February 24, 2025. The company must boost its share price to at least $1.00 for 10 consecutive business days before this deadline to regain compliance. If compliance is not achieved, NeuroSense may be granted an additional 180 days if it meets other listing standards. The company's operations remain unaffected by this notification, and it is actively monitoring its share price to address the deficiency within the compliance period. NeuroSense specializes in developing treatments for neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's disease.